Study calls for more cautious use of Tamiflu in children
This article was originally published in Scrip
A study has found that treating influenza in children with Roche's antiviral Tamiflu (oseltamivir) or GlaxoSmithKline's rival drug Relenza (zanamivir) provides only a small improvement in the length of illness (between 0.5 and 1.5 days), casting doubt over their usefulness for the current pandemic.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.